<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Poor prognosis in patients with later stage <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>) necessitates the search for new treatment strategies </plain></SENT>
<SENT sid="1" pm="."><plain><z:chebi fb="7" ids="17761">Ceramide</z:chebi>, because of its role in orchestrating <z:hpo ids='HP_0011420'>death</z:hpo> cascades in <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> cells, is a versatile alternative </plain></SENT>
<SENT sid="2" pm="."><plain><z:chebi fb="7" ids="17761">Ceramide</z:chebi> can be generated by exposure to chemotherapy or ionizing radiation, or it can be administered in the form of short-chain analogs (C6-<z:chebi fb="7" ids="17761">ceramide</z:chebi>) </plain></SENT>
<SENT sid="3" pm="."><plain>Because intracellular P-<z:chebi fb="2" ids="17089">glycoprotein</z:chebi> (P-gp) plays a role in catalyzing the conversion of <z:chebi fb="7" ids="17761">ceramide</z:chebi> to higher <z:chebi fb="0" ids="26739">sphingolipids</z:chebi>, we hypothesized that administration of P-gp <z:chebi fb="68" ids="48706">antagonists</z:chebi> with C6-<z:chebi fb="7" ids="17761">ceramide</z:chebi> would magnify cell <z:hpo ids='HP_0011420'>death</z:hpo> cascades </plain></SENT>
<SENT sid="4" pm="."><plain>Human <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> cell lines were employed, HCT-15, HT-29, and LoVo </plain></SENT>
<SENT sid="5" pm="."><plain>The addition of either <z:chebi fb="3" ids="41774">tamoxifen</z:chebi>, VX-710, <z:chebi fb="1" ids="9948">verapamil</z:chebi>, or <z:chebi fb="0" ids="4031">cyclosporin A</z:chebi>, <z:chebi fb="68" ids="48706">antagonists</z:chebi> of P-gp, enhanced C6-<z:chebi fb="7" ids="17761">ceramide</z:chebi> cytotoxicity in <z:hpo ids='HP_0000001'>all</z:hpo> cell lines </plain></SENT>
<SENT sid="6" pm="."><plain>In depth studies with C6-<z:chebi fb="7" ids="17761">ceramide</z:chebi> and <z:chebi fb="3" ids="41774">tamoxifen</z:chebi> in LoVo cells showed the regimen induced PARP cleavage, caspase-dependent <z:mpath ids='MPATH_3'>apoptosis</z:mpath>, <z:hpo ids='HP_0001427'>mitochondrial</z:hpo> membrane permeabilization (MMP), and cell cycle arrest at G1 and G2 </plain></SENT>
<SENT sid="7" pm="."><plain>At the molecular level, the regimen, but not single agents, induced time-dependent upregulation of <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> suppressor protein p53; however, introduction of a p53 inhibitor staved neither MMP nor <z:mpath ids='MPATH_3'>apoptosis</z:mpath> </plain></SENT>
<SENT sid="8" pm="."><plain>Nanoliposomal formulations of C6-<z:chebi fb="7" ids="17761">ceramide</z:chebi> and <z:chebi fb="3" ids="41774">tamoxifen</z:chebi> were also effective, yielding synergistic cell kill </plain></SENT>
<SENT sid="9" pm="."><plain>We conclude that <z:chebi fb="3" ids="41774">tamoxifen</z:chebi> is a favorable adjuvant for enhancing C6-<z:chebi fb="7" ids="17761">ceramide</z:chebi> cytotoxicity in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>, and demonstrates uniquely integrated effects </plain></SENT>
<SENT sid="10" pm="."><plain>The high frequency of expression of P-gp in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> presents an adventitious target for complementing <z:chebi fb="7" ids="17761">ceramide</z:chebi>-based therapies, a strategy that could hold promise for treatment of resistant disease </plain></SENT>
</text></document>